抗抑郁药或与心血管病炎性标志物较高有关

　　6月13日在线发表于《美国公共卫生杂志》（Am J Public Health）的一项新流行病学研究表明，抑郁症状和应用抗抑郁药与糖尿病和心血管疾病（CVD）风险相关的标志物具有相关性。

　　这项研究纳入了“女性健康倡议”（WHI）中超过2000名的绝经后女性受试者，研究显示，与健康受试者相比，那些抑郁症状较严重并且应用了抗抑郁药物的患者炎性生物标志物C—反应蛋白水平明显更可能较高，且其体质指数（BMI）和腰围更可能较高。

Relations of Depressive Symptoms and Antidepressant Use to Body Mass Index and Selected Biomarkers for Diabetes and Cardiovascular Disease
Objectives
We investigated whether depressive symptoms and antidepressant use are associated with biomarkers for glucose dysregulation and inflammation, body mass index (BMI), and waist circumference.
Methods
Postmenopausal women were recruited into the Women's Health Initiative from 1993 to 1998, and data were collected at regular intervals through 2005. We used multiple linear regression models to examine whether depressive symptoms and antidepressant use are associated with BMI, waist circumference, and biomarkers.
Results
Analysis of data from 71 809 women who completed all relevant baseline and year 3 assessments showed that both elevated depressive symptoms and antidepressant use were significantly associated with higher BMI and waist circumference. Among 1950 women, elevated depressive symptoms were significantly associated with increased insulin levels and measures of insulin resistance. Analyses of baseline data from 2242 women showed that both elevated depressive symptoms and antidepressant use were associated with higher C-reactive protein levels.
Conclusions
Monitoring body habitus and other biomarkers among women with elevated depression symptoms or taking antidepressant medication may be prudent to prevent diabetes and cardiovascular disease.